Trial · NCT03158948
Adverse events148
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
81 to 100 of 148
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Cardio-respiratory arrest | Cardiac disorders | Placebo | 0 | 12 | 0 |
| serious | Cardio-respiratory arrest | Cardiac disorders | Nangibotide 0.3 mg/kg/h | 1 | 13 | 1 |
| serious | Cardio-respiratory arrest | Cardiac disorders | Nangibotide 1.0 mg/kg/h | 0 | 12 | 0 |
| serious | Cardio-respiratory arrest | Cardiac disorders | Nangibotide 3.0 mg/kg/h | 0 | 12 | 0 |
| serious | Encephalitis | Infections and infestations | Placebo | 0 | 12 | 0 |
| serious | Encephalitis | Infections and infestations | Nangibotide 0.3 mg/kg/h | 1 | 13 | 1 |
| serious | Encephalitis | Infections and infestations | Nangibotide 1.0 mg/kg/h | 0 | 12 | 0 |
| serious | Encephalitis | Infections and infestations | Nangibotide 3.0 mg/kg/h | 0 | 12 | 0 |
| serious | Post procedural haemorrhage | Injury, poisoning and procedural complications | Placebo | 0 | 12 | 0 |
| serious | Post procedural haemorrhage | Injury, poisoning and procedural complications | Nangibotide 0.3 mg/kg/h | 1 | 13 | 1 |
| serious | Post procedural haemorrhage | Injury, poisoning and procedural complications | Nangibotide 1.0 mg/kg/h | 0 | 12 | 0 |
| serious | Post procedural haemorrhage | Injury, poisoning and procedural complications | Nangibotide 3.0 mg/kg/h | 0 | 12 | 0 |
| serious | Multiple organ failure syndrome | General disorders | Placebo | 0 | 12 | 0 |
| serious | Multiple organ failure syndrome | General disorders | Nangibotide 0.3 mg/kg/h | 0 | 13 | 0 |
| serious | Multiple organ failure syndrome | General disorders | Nangibotide 1.0 mg/kg/h | 1 | 12 | 1 |
| serious | Multiple organ failure syndrome | General disorders | Nangibotide 3.0 mg/kg/h | 0 | 12 | 0 |
| serious | Haemodynamic instability | Vascular disorders | Placebo | 0 | 12 | 0 |
| serious | Haemodynamic instability | Vascular disorders | Nangibotide 0.3 mg/kg/h | 0 | 13 | 0 |
| serious | Haemodynamic instability | Vascular disorders | Nangibotide 1.0 mg/kg/h | 1 | 12 | 1 |
| serious | Haemodynamic instability | Vascular disorders | Nangibotide 3.0 mg/kg/h | 0 | 12 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03158948/events?page=5